Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Citi
Daiichi Sankyo
McKesson
Merck
UBS
Cipla
Mallinckrodt

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,969,566

« Back to Dashboard

Which drugs does patent 8,969,566 protect, and when does it expire?

Patent 8,969,566 protects AVYCAZ and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.
Summary for Patent: 8,969,566
Title:Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), ##STR00001## including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
Inventor(s): Ronsheim; Melanie Simone (Port Jefferson, NY), Racha; Saibaba (Smithtown, NY), Lawton; Graham Richard (Smithtown, NY), Zhou; Shao Hong (Commack, NY), Kalyan; Yuriy B. (Staten Island, NY), Golden; Michael (Macclesfield, GB), Milne; David (Macclesfield, GB), Telford; Alexander (Macclesfield, GB), Cherryman; Janette (Macclesfield, GB), Boyd; Alistair (Cheshire, GB), Phillips; Andrew (Macclesfield, GB), Dedhiya; Mahendra G. (Pomona, NY)
Assignee:
Application Number:14/180,656
Patent Claim Types:
see list of patent claims
Use; Compound; Process;

Drugs Protected by US Patent 8,969,566

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,969,566

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,695,122 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof ➤ Sign Up
8,829,191 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof ➤ Sign Up
9,284,314 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Chubb
US Department of Justice
Citi
Deloitte
AstraZeneca
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.